Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86). As of December 31, 2023, cash equivalents and investments were $218.1 million. The company says the cash balance and the ability to draw down an additional $40 million of its term loan are sufficient to fund planned operations into early 2026. In October 2023, ALX Oncology released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab), and paclitaxel for HER2-positive gastric/gastroesophageal junction cance…
